Memo Therapeutics AG moves towards clinical development of anti-coronavirus asset

The D-BSSE spin-off company is an innovator in the field of antibody discovery and immune repertoire analysis and as such, works at the forefront of identifying potent antibodies for the immunotherapy of COVID-19 patients. By raising Series B financing, the company now moves forward towards clinical development of two antiviral assets, including Phase 2 clinical studies and the production of GMP material, beginning in 2021.